Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.
The Australian Workers Union has called on the Federal Court to toss AstraZeneca’s challenge to a decision that workers are guaranteed 10 days’ sick leave regardless of how long their working day is.
The judge overseeing a class action against American Medical Systems over allegedly defective pelvic mesh implants has rejected the medical device maker’s bid to alter the start date for a sub-group of class members.
Public hospital operators in NSW have been hit with a class action over a practice of forcing non-resident patients ineligible for Medicare cards to find Australian citizens to be guarantors before they are treated.
Generic drug company Apotex has settled a patent infringement case brought by global pharmaceutical giant Lundbeck over its blockbuster antidepressant Lexapro.
The High Court has dismissed the ACCC’s bid to appeal a Full Federal Court decision upholding a ruling that drug giant Pfizer did not misuse its market power in the months leading up to the expiration of the patent for its blockbuster cholesterol drug Lipitor.
AFT Pharmaceuticals breached the consumer laws with misleading ads over the strength of its painkiller Maxigesic, a judge has found, siding with rival drug maker Reckitt Benckiser.
The Commonwealth of Australia has resolved its claims against pharmaceutical giant Wyeth over the price it paid to list Effexor on the PBS, months after a high stakes trial wrapped up.
Medical device maker American Medical Systems, which is facing a class action over allegedly faulty pelvic mesh implants, has taken a page from the Ethicon pelvic mesh defence playbook, calling on the court to restrict the dates for group membership.
A South Korean biotech company has filed an appeal with the Federal Court after an Ashurst partner succeeded in opposing the company’s proposed patent for a genome editing technology.